Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin

BACKGROUND The B subunit of Escherichia coli heat-labile enterotoxin (LTB) is a potent mucosal immune adjuvant. However, there is little information about LTB's potential as a parenteral adjuvant. OBJECTIVES We aimed at evaluating and better understanding rLTB's potential as a parenteral adjuvant using the fused R1 repeat of Mycoplasma hyopneumoniae P97 adhesin as an antigen to characterise the humoral immune response induced by this construct and comparing it to that generated when aluminium hydroxide is used as adjuvant instead. METHODS BALB/c mice were immunised intraperitoneally with either rLTBR1 or recombinant R1 adsorbed onto aluminium hydroxide. The levels of systemic anti-rR1 antibodies (total Ig, IgG1, IgG2a, and IgA) were assessed by enzyme-linked immunosorbent assay (ELISA). The ratio of IgG1 and IgG2a was used to characterise a Th1, Th2, or mixed Th1/Th2 immune response. FINDINGS Western blot confirmed rR1, either alone or fused to LTB, remained antigenic; anti-cholera toxin ELISA confirmed that LTB retained its activity when expressed in a heterologous system. Mice immunised with the rLTBR1 fusion protein produced approximately twice as much anti-rR1 immunoglobulins as mice vaccinated with rR1 adsorbed onto aluminium hydroxide. Animals vaccinated with either rLTBR1 or rR1 adsorbed onto aluminium hydroxide presented a mixed Th1/Th2 immune response. We speculate this might be a result of rR1 immune modulation rather than adjuvant modulation. Mice immunised with rLTBR1 produced approximately 1.5-fold more serum IgA than animals immunised with rR1 and aluminium hydroxide. MAIN CONCLUSIONS The results suggest that rLTB is a more powerful parenteral adjuvant than aluminium hydroxide when administered intraperitoneally as it induced higher antibody titres. Therefore, we recommend that rLTB be considered an alternative adjuvant, even if different administration routes are employed.

[1]  C. Exley The toxicity of aluminium in humans. , 2016, Morphologie : bulletin de l'Association des anatomistes.

[2]  M. Liao,et al.  Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice. , 2016, Vaccine.

[3]  P. Milburn,et al.  The B subunit of Escherichia coli heat-labile toxin alters the development and antigen-presenting capacity of dendritic cells , 2015, Journal of cellular and molecular medicine.

[4]  S. Eo,et al.  Comparison of a live attenuated Salmonella Enteritidis vaccine candidate secreting Escherichia coli heat-labile enterotoxin B subunit with a commercial vaccine for efficacy of protection against internal egg contamination by Salmonella in hens. , 2015, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[5]  Zhong-yu Hu,et al.  Advances in aluminum hydroxide-based adjuvant research and its mechanism , 2015, Human vaccines & immunotherapeutics.

[6]  D. Maes,et al.  Immune responses of a chimaeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs. , 2014, Vaccine.

[7]  F. Conceição,et al.  Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D. , 2014, Vaccine.

[8]  F. Conceição,et al.  Recombinant Escherichia coli heat-labile enterotoxin B subunit humoral adjuvant effect depends on dose and administration route , 2010 .

[9]  Jeffrey A. Hubbell,et al.  Materials engineering for immunomodulation , 2009, Nature.

[10]  F. Conceição,et al.  B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination. , 2008, Canadian journal of microbiology.

[11]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[12]  E. Miyaji,et al.  Optimized Immune Response Elicited by a DNA Vaccine Expressing Pneumococcal Surface Protein A Is Characterized by a Balanced Immunoglobulin G1 (IgG1)/IgG2a Ratio and Proinflammatory Cytokine Production , 2008, Clinical and Vaccine Immunology.

[13]  F. Conceição,et al.  A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice. , 2006, Vaccine.

[14]  J. Brewer (How) do aluminium adjuvants work? , 2006, Immunology letters.

[15]  A. Matsukawa,et al.  INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS , 2004, Shock.

[16]  T. Hirst,et al.  Escherichia coli Heat-Labile Enterotoxin B Subunit Is a More Potent Mucosal Adjuvant than Its Closely Related Homologue, the B Subunit of Cholera Toxin , 2001, Infection and Immunity.

[17]  J. Wilschut,et al.  Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. , 2001, Vaccine.

[18]  R. Mitchell,et al.  Evidence for a role of ganglioside GM1 in antigen presentation: binding enhances presentation of Escherichia coli enterotoxin B subunit (EtxB) to CD4(+) T cells. , 2001, International immunology.

[19]  G. Dougan,et al.  Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. , 2001, Vaccine.

[20]  J. Mcghee,et al.  Genetically Manipulated Bacterial Toxin as a New Generation Mucosal Adjuvant , 2001, Scandinavian journal of immunology.

[21]  T. Hirst,et al.  Protective Mucosal Immunity to Ocular Herpes Simplex Virus Type 1 Infection in Mice by Using Escherichia coli Heat-Labile Enterotoxin B Subunit as an Adjuvant , 2001, Journal of Virology.

[22]  N. Williams Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic. , 2000, International journal of medical microbiology : IJMM.

[23]  B. Guy,et al.  Parenteral Adjuvant Activities of Escherichia coli Heat-Labile Toxin and Its B Subunit for Immunization of Mice against Gastric Helicobacter pyloriInfection , 2000, Infection and Immunity.

[24]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[25]  C. Power,et al.  Mycobacterial Dose Defines the Th1/Th2 Nature of the Immune Response Independently of Whether Immunization Is Administered by the Intravenous, Subcutaneous, or Intradermal Route , 1998, Infection and Immunity.

[26]  T. Hirst,et al.  Modulation of B‐cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up‐regulates MHC class II, B7, CD40, CD25 and ICAM‐1 , 1997, Immunology.

[27]  K. Dzierzbicka,et al.  [Adjuvants--essential components of new generation vaccines]. , 2006, Postepy biochemii.

[28]  H. W. Jackeman Diseases of Swine. , 1940, Canadian journal of comparative medicine and veterinary science.